SHENZHEN, China, July 17 Mindray MedicalInternational Limited (NYSE: MR), a leading developer, manufacturer andmarketer of medical devices worldwide has announced today that it willhighlight all of its marketed in-vitro diagnostic products as well as unveilthree new units and reagents at the 2008 Annual American Association forClinical Chemistry (AACC) conference. The conference will be attended by Mr.Jie Liu, Executive Vice President of International Sales & Marketing and Mr.Wei Wang, Vice President of Research and Development.
Mindray will showcase its entire line of in-vitro diagnostic products atthe conference, along with three demo units: the BC-5300 and BC-5380, both ofwhich are Hematology Analyzers, the BA-88A, a Semi-automatic BiochemistryAnalyzer, and the first five reagents for the Biochemistry Analyzer. Allproducts are expected to enter the international market in the second half of2008.
"Mindray's presence at this conference speaks volumes about the directionin which the company is heading," commented Mr. Li Xiting, Mindray's Presidentand Co-Chief Executive Officer. "Presenting at the AACC conference allows usto showcase our high quality products, and demonstrate their efficacy to themedical community."
Mindray's products will be on display at AACC booth 825 in Hall A. The60th Annual AACC conference will take place from July 29 through July 31 atthe Washington Convention Center in Washington D.C. AACC is an internationalsociety comprised of medical professionals with an interest in clinicalchemistry, clinical laboratory science, and laboratory medicine. Founded in1948, the society has over 9,000 members and is headquartered in Washington,D.C.
Mindray is a leading developer, manufacturer and marketer of medicaldevices worldwide. Established in 1991, Mindray offers a broad range ofproducts across three primary business segments: patient monitoring & lifesupport products, in-vitro diagnostic products and medical imaging systems.Mindray is globally headquartered in Shenzhen, China, with U.S. headquartersin Mahwah, New Jersey. Mindray also has another 12 international sales andservice offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow,Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver.
For more information, please visit http://www.mindray.com .
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by terminology such as "will," "expects," "anticipates," "future,""intends," "plans," "believes," "estimates," "confident" and similarstatements. Statements that are not historical facts, including statementsabout Mindray's beliefs and expectations, are forward-looking statements.Forward-looking statements involve inherent risks and uncertainties.Information regarding these risks and uncertainties is included in our publicfilings with the Securities and Exchange Commission. All information providedin this press release is as of July 17, 2008, and Mindray undertakes no dutyto update such information, except as required under applicable law.For investor and media inquiries, please contact: In the U.S: Evan Smith, FD Tel: +1-212-850-5606 Email: firstname.lastname@example.org John Capodanno, FD Tel: +1-212-850-5705 Email: email@example.com In China: Susan Du Mindray Medical International Limited Tel: +86-755-2658-2518 Email: Susan.Du@Mindray.com
SOURCE Mindray Medical International Limited